

DAFTAR PUSTAKA

1. Bray, F. Et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA* 68, 394–424.
2. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D., Piñeros, M., Znaor, A. and Bray, F. (2019), Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer*, 144: 1941-1953. doi:10.1002/ijc.31937.
3. International Agency for Research on Cancer (2019) *Cancer Tomorrow*. International Agency for Research on Cancer.
4. Keen J. 2008. Commentary: a step towards a new targeted nanotherapy for pancreatic cancer. *Cancer Biol Ther* 2008;7(10):1591-2
5. Chidambaran M., Manavalan R., and Kathiresan K.: Nano-therapeutics to overcome conventional cancer chemotherapy limitations. *J. Pharm. Pharm. Sci.* 2011; 14: pp. 67-77
6. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. 2011. Tumor suppressor gene-based nanotherapy : from test tube to the clinic. *J Drug Deliv* 2011;1-10
7. Hoshyar N., Gray S., Han H., and Bao G.: The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. *Nanomedicine* 2016; 11: pp. 673-692
8. Piktel E., Niemirowicz K., Wątek M., Wollny T., Deptuła P., and Bucki R.: Recent insights in nano-technology-based drugs and formulations designed for effective anti-cancer therapy. *J. Nanobiotechnology* 2016; 14: pp. 39
9. Ventola C.L.: The nanomedicine revolution: part 2: current and future clinical applications. *P T* 2012; 37: pp. 582-591
10. Pillai G.: Nano-medicines for cancer therapy: an update of FDA approved and those under various stages of development. *SOJ Pharm. Pharm. Sci.* 2014; 1: pp. 13
11. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. *FASEB J.* 19(3), 311–330 (2005).
12. Chang EH, Harford JB, Eaton MaW et al. Nanomedicine: past, present and future – A global perspective. *Biochem. Biophys. Res. Commun.* 468(3), 511–517 (2015).
13. Young SWS, Stenzel M, Jia-Lin Y. Nanoparticle-siRNA: a potential cancer therapy? *Crit. Rev. Oncol. Hematol.* 98, 159–169 (2016).
14. Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. *Adv. Drug Deliv. Rev.* 62(3), 362–374 (2010).
15. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. *Nanomedicine* 8(3), 449–467



omis K, Smith B et al. Lipid-based nanoparticles as pharmaceutical drug
om concepts to clinic. *Crit. Rev. Ther. Drug Carrier Syst.* 26(6), 523–580

17. Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. *Adv. Colloid Interface Sci.* 147–148 333–342 (2009).
18. Wibroe PP, Mat Azmi ID, Nilsson C, Yaghmur A, Moghimi SM. Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers. *Nanomedicine* 11(8), 1909–1914 (2015).
19. Tang F., Li L., and Chen D.: Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. *Adv. Mater* 2012; 24: pp. 1504-1534
20. Brigger I., Dubernet C., and Couvreur P.: Nanoparticles in cancer therapy and diagnosis. *Adv. Drug Deliv. Rev.* 2012; 54: pp. 631-651
21. Desai M.P., Labhsetwar V., Amidon G.L., and Levy R.J.: Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm. Res.* 1996; 13: pp. 1838-1845
22. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJ.: Nanotoxicology. *Occup Environ Med.* 2004
23. Chow EK-H, Ho D. Cancer nanomedicine: from drug delivery to imaging. *Sci. Transl. Med.* 5(216), 216rv214–216rv214 (2013)
24. Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. *SOJ Pharm. Pharm. Sci.* 1(2), 13 (2014)
25. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. *Int. J. Nanomed.* 7, 49–60 (2012)
26. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. *Nanomedicine* 2010
27. Zhou Y., et al: Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. *J. Mol. Biol.* 2007; 371: pp. 934-947
28. Kirpotin D.B., et al: Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. *Cancer Res.* 2006; 66: pp. 6732-6740
29. Desai N.: Challenges in development of nanoparticle-based therapeutics. *AAPS J.* 2012; 14: pp. 282-295
30. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacol Rev.* 2001;53(2):283–318.
31. Bertrand N., et al: Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Adv. Drug Deliv. Rev.* 2014; 66: pp. 2-25
32. Kamaly N., et al: Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. *Chem. Soc. Rev.* 2012; 41: pp. 2971-3010



A., et al: Overcoming Wiley Interdiscip. *Rev. Nanomed. Nanobiotechnol.* 2011; -437

et al: Designing the nanoparticle-biomolecule interface for “targeting and ic delivery”. *J. Control. Release* 2012; 161: pp. 164-174

35. Ma D.D., and Yang W.X.: Engineered nanoparticles induce cell apoptosis: potential for cancer therapy. *Oncotarget* 2016; 4: pp. 40882-40903
36. Xia T., et al: Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. *ACS Nano* 2008; 2: pp. 2121-2134
37. Anguela X.M., and High K.A.: Entering the modern era of gene therapy. *Annu. Rev. Med.* 2019; 70: pp. 273-288
38. Kong N., et al: Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. *Sci. Transl. Med.* 2019; 11:
39. Patel A.K., et al: Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. *Adv. Mater.* 2019; 31:
40. Oberli M.A., et al: Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. *Nano Lett.* 2017; 17: pp. 1326-1335
41. Chauhan V.P., et al: Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. *Proc. Natl. Acad. Sci. U. S. A.* 2019; 116: pp. 10674-10680
42. Chiang C.-S., et al: Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. *Nat. Nanotechnol.* 2018; 13: pp. 746-754
43. Schmid D., et al: T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. *Nat. Commun.* 2017; 8: pp. 1747



LAMPIRAN

Lampiran 1 (Biodata Penulis)



Nama Lengkap : Wahyuddin
NIM : C011171331
Tempat, Tanggal Lahir : Merauke, 28 Juni 1999
Jenis Kelamin : Laki-laki
Alamat : Perumahan Graha Tiga Putra Blok C No 10.
Jalan Tamlanrea Utara 4
No. Telp : 081340047855
Nama Orang Tua
Ayah : Muslimin
Ibu : Tanawali
Fakultas / Angkatan : Kedokteran / 2017
Email : wahyuddin.78.mustan@gmail.com
Riwayat Pendidikan :

Jenjang Pendidikan	Nama Sekolah	Tahun
Sekolah Dasar	SD Inpres Polder Merauke	2006 – 2011
Sekolah Menengah Pertama	SMP Negeri 1 Merauke	2011 – 2014
Menengah Atas	SMA Negeri 1 Merauke	2014 – 2017
n Tinggi	Universitas Hasanuddin	2017 - sekarang





Optimized using
trial version
www.balesio.com